Table 2.
Medication use among REGARDS participants hospitalized for HFrEF
| Admission medication lista | Discharge medication lista | Claims within 1 yearb | |
|---|---|---|---|
| Beta-blocker | |||
| Discharged home | 74% | 81% | 66% |
| Discharged to long-term care | 82% | 95% | 68% |
| HFrEF beta-blockerc | |||
| Discharged home | 52% | 60% | 49% |
| Discharged to long-term care | 50% | 68% | 50% |
| ACEI/ARB | |||
| Discharged home | 41% | 54% | 47% |
| Discharged to long-term care | 41% | 55% | 45% |
| Diuretic | |||
| Discharged home | 71% | 87% | 72% |
| Discharged to long-term care | 77% | 86% | 50% |
| Loop diuretic | |||
| Discharged home | 66% | 85% | 70% |
| Discharged to long-term care | 77% | 86% | 50% |
| Hydralazine in combination with isosorbide dinitrate | |||
| Discharged home | 14% | 23% | 23% |
| Discharged to long-term care | 9% | 5% | 5% |
| Aldosterone receptor antagonist | |||
| Discharged home | 14% | 22% | 23% |
| Discharged to long-term care | 9% | 14% | 5% |
HFrEF Heart failure with reduced ejection fraction, ACEI/ARB Angiotensin converting enzyme inhibitor or angiotensin receptor blocker
aDetermined from review of medical records
bDetermined using Medicare pharmacy claims data
cCarvedilol, metoprolol succinate, or bisoprolol